Stocksigma LogoStocksigma Logo

Glenmark Pharma Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth

Glenmark Pharmaceuticals reported Q2 FY27 consolidated revenue of Rs. 42,473 Mn, delivering ~20% like-for-like YoY growth and 5.7% QoQ growth

Glenmark Pharma Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth

Glenmark Pharmaceuticals Ltd 路 Investor Presentation 路 05 Nov 2026, 10:55 pm

Glenmark Pharma Reports Q2 FY27 Results with 20% Like-for-Like Revenue Growth Glenmark Pharmaceuticals reported Q2 FY27 consolidated revenue of Rs. 42,473 Mn, delivering ~20% like-for-like YoY growth and 5.7% QoQ growth. EBITDA stood at Rs. 8,638 Mn with a 20.3% margin, while adjusted PAT reached Rs. 4,852 Mn with an 11.4% margin. Key regional growth drivers included Emerging Markets (+33.2% YoY), North America core business (~31% YoY), India formulations (~14% YoY like-for-like), and Europe (+6.2% YoY). Consolidated R&D expense totaled Rs. 3,449 Mn as the company advanced its clinical oncology pipeline toward commercialization.

Original exchange filing (PDF)

More announcements from Glenmark Pharmaceuticals Ltd

All Glenmark Pharmaceuticals Ltd announcements